Related Experiment Video
Updated: May 3, 2026
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Significance of platelet and AFP levels and liver function parameters for HCC size and survival
Brian I Carr1, Vito Guerra, Edoardo G Giannini
1IRCCS de Bellis, Bari - Italy.
Insights
Tumor size in hepatocellular carcinoma (HCC) correlates with alpha-fetoprotein (AFP) and gamma-glutamyl transpeptidase (GGTP) levels. While AFP and platelet counts indicate tumor size, they do not predict patient survival.
Area of Science:
- Hepatology
- Oncology
- Clinical Research
Background:
- Hepatocellular carcinoma (HCC) is a complex cancer influenced by both tumor characteristics and liver health.
- Understanding HCC heterogeneity is crucial for effective patient management.
Purpose of the Study:
- To analyze clinical phenotypes of HCC patients.
- To identify factors associated with hepatocellular carcinoma tumor size.
Main Methods:
- Prospective data from a large Italian HCC patient database were utilized.
- Patients were stratified into tumor size terciles based on maximum tumor diameter (MTD).
- Clinical parameters and survival rates were compared across different tumor size groups.
Main Results:
- Increased MTD terciles correlated with higher alpha-fetoprotein (AFP), gamma-glutamyl transpeptidase (GGTP), and platelet levels.
- Higher platelet counts were linked to larger tumors and elevated GGTP, but lower bilirubin.
- Elevated AFP levels indicated larger tumors and higher bilirubin, suggesting aggressive tumor biology.
- Cox analysis identified GGTP, bilirubin, tumor size/number, and portal vein thrombosis (PVT) as mortality predictors, not AFP or platelets.
Conclusions:
- Tumor size in HCC is associated with elevated platelet counts, AFP, and GGTP.
- Platelet and AFP levels serve as indicators of tumor size.
- AFP and platelet levels are not significant predictors of HCC patient survival.
Background:
Hepatocellular carcinoma (HCC) is a heterogeneous disease with both tumor and liver factors being involved.
Aims:
To investigate HCC clinical phenotypes and factors related to HCC size.
Methods:
Prospectively-collected HCC patients' data from a large Italian database were arranged according to the maximum tumor diameter (MTD) and divided into tumor size terciles, which were then compared in terms of several common clinical parameters and patients' survival.
Results:
An higer MTD tercile was significantly associated with increased blood alpha-fetoprotein (AFP), gamma-glutamyl transpeptidase (GGTP), and platelet levels. Patients with higher platelet levels had larger tumors and higher GGTP levels, with lower bilirubin levels. However, patients with the highest AFP levels had larger tumors and higher bilirubin levels, reflecting an aggressive biology. AFP correlation analysis revealed the existence of 2 different groups of patients: those with higher and with lower AFP levels, each with different patient and tumor characteristics. The Cox proportional-hazard model showed that a higher risk of death was correlated with GGTP and bilirubin levels, tumor size and number, and portal vein thrombosis (PVT), but not with AFP or platelet levels.
Conclusions:
An increased tumor size was associated with increased blood platelet counts, AFP and GGTP levels. Platelet and AFP levels were important indicators of tumor size, but not of survival.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow